<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078051</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0647</org_study_id>
    <nct_id>NCT01078051</nct_id>
  </id_info>
  <brief_title>Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)</brief_title>
  <official_title>Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of drug-eluting stent
      implantation compared to optimal medical treatment in patients with chronic total occlusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, two arms, randomized multi-center trial in Asian-pacific region. Following
      angiography, patients with chronic total occlusion (more than 3 months) have documented
      myocardial ischemia or symptoms of angina, and eligible for stenting without any exclusion
      criteria will be randomized 1:1 to: a) drug-eluting stent vs. b) optimal medical treatment.
      All patients will be followed for at least 3 year.

      The subjects with chronic total occlusion but failed to random for any reason, they will be
      enrolled in registry group.

      The random design was closed at the date of 22 July 2019 however already randomized subjects
      and subjects from registry design continue 10 years follow-up on IRIS-CTO registry.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    at sponsor's discretion : Benefit is not guaranteed
  </why_stopped>
  <start_date type="Actual">March 22, 2010</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcomes of all cause death, myocardial infarction, stroke, and any revascularization for 3 years after randomization</measure>
    <time_frame>at 3 years</time_frame>
    <description>at the median of 3 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Death (Cardiac death)</measure>
    <time_frame>at 3 years &amp; 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina class; Quality of life, clinical outcomes at 5 years</measure>
    <time_frame>at 3 years &amp; 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction, stroke,any revascularization, CTO-vessel related revascularization, hospitalization due to acute coronary syndrome, left ventricular ejection fraction</measure>
    <time_frame>at 3 years &amp; 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">840</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Optimal medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>optimal medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cypher, xience, Endeavor, Taxus</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cypher, xience, Endeavor, Taxus</intervention_name>
    <description>all species of drug-eluting stent implantation</description>
    <arm_group_label>drug-eluting stent</arm_group_label>
    <other_name>percutaneous coronary intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>optimal medical therapy</intervention_name>
    <description>optimal medical therapy</description>
    <arm_group_label>Optimal medical therapy</arm_group_label>
    <other_name>intensive medical therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical

          1. Patients with angina or silent ischemia and documented ischemia

          2. Patients who are eligible for intracoronary stenting

          3. Age &gt; 18 years

        Angiographic

          1. De novo lesion CTO

          2. Reference vessel size 2.5 mm by visual estimation

          3. At least one CTO lesions located in proximal or mid epicardial coronary artery. (If
             the patient has two CTO lesions, one CTO lesion should be located in proximal or mid
             epicardial coronary artery)

        CTO definition: TIMI flow 0 and estimated duration over 3 months The duration of the
        occlusion was determined by the interval from the last episode of acute coronary syndrome,
        or In patients without a history of acute coronary syndrome, from the first episode of
        effort angina consistent with the location of the occlusion

          1. Angiographically defined total occlusion over 3 months

          2. If no definite symptom with total occlusion, two experienced operators decide CTO in
             consideration of angiographical morphology (degree of calcification, bridging
             collaterals, non-tapered stump, angiographic filling from collaterals)

        Exclusion Criteria:

          1. History of bleeding diathesis or coagulopathy

          2. Pregnant state

          3. Three vessel CTO

          4. Known hypersensitivity or contra-indication to contrast agent and heparin

          5. ST-elevation acute myocardial infarction requiring primary stenting

          6. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels
             4) Distal epicardial coronary artery CTO lesions

          7. Hematological disease

          8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation 3 times normal

          9. Renal dysfunction, creatinine more than 2.0

         10. Contraindication to aspirin, clopidogrel or other commercial antiplatelet agent

         11. Left ventricular ejection fraction

         12. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.

         13. Non-cardiac co-morbid conditions are present with limited life expectancy or that may
             result in protocol non-compliance (per site investigator's medical judgment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>I</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medistra Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sam Anyang Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital, Buchen</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital, Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST.Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GangNeung Asan Hospital</name>
      <address>
        <city>GangNeung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center, Hangang Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Kangnam ST.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang CHA Hospital</name>
      <address>
        <city>S≈èngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Kong Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <keyword>chronic total occlusion</keyword>
  <keyword>stent</keyword>
  <keyword>medical therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not a publicly funded trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

